International Journal of Science, Engineering and TechnologyAuthors: Research Scholar Prasun Kumar Verma, Professor Dr.Ankit Singh, Dr.G.Vijaya Kumar
Abstract: Background: SGLT2 inhibitors and GLP-1 receptor agonists (GLP-1 RAs) are widely used for type 2 diabetes mellitus (T2DM). Their effects differ across blood glucose, body weight, cardiovascular health, kidney protection and adverse events. Objective: To summarize selected published evidence from 1 January 2022 to 31 December 2024 and present a reproducible plan for a later systematic review and meta-analysis. Methods: A focused narrative assessment of verified peer-reviewed publications and clinical guidance published during 2022–2024 was undertaken. The planned formal review will use predefined eligibility criteria, duplicate screening, risk-of-bias assessment and quantitative synthesis when data permit. Findings: Available evidence supports clinically important benefits for both classes. SGLT2 inhibitors are especially relevant to heart-failure and kidney outcomes, whereas selected GLP-1 RAs provide strong glucose and weight effects and cardiovascular benefit. Safety profiles differ and require individualized choice. Conclusion: Neither drug class is best for every patient. A fully conducted head-to-head meta-analysis remains necessary for precise comparative estimates.
